Guerrero-Mauvecin, J.; Villar-Gómez, N.; Miño-Izquierdo, L.; Povo-Retana, A.; Ramos, A.M.; Ruiz-Hurtado, G.; Sanchez-Niño, M.D.; Ortiz, A.; Sanz, A.B.
Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Antioxidants 2025, 14, 701.
https://doi.org/10.3390/antiox14060701
AMA Style
Guerrero-Mauvecin J, Villar-Gómez N, Miño-Izquierdo L, Povo-Retana A, Ramos AM, Ruiz-Hurtado G, Sanchez-Niño MD, Ortiz A, Sanz AB.
Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Antioxidants. 2025; 14(6):701.
https://doi.org/10.3390/antiox14060701
Chicago/Turabian Style
Guerrero-Mauvecin, Juan, Natalia Villar-Gómez, Lucia Miño-Izquierdo, Adrián Povo-Retana, Adrian M. Ramos, Gema Ruiz-Hurtado, Maria D. Sanchez-Niño, Alberto Ortiz, and Ana B. Sanz.
2025. "Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome" Antioxidants 14, no. 6: 701.
https://doi.org/10.3390/antiox14060701
APA Style
Guerrero-Mauvecin, J., Villar-Gómez, N., Miño-Izquierdo, L., Povo-Retana, A., Ramos, A. M., Ruiz-Hurtado, G., Sanchez-Niño, M. D., Ortiz, A., & Sanz, A. B.
(2025). Antioxidant Effects of SGLT2 Inhibitors on Cardiovascular–Kidney–Metabolic (CKM) Syndrome. Antioxidants, 14(6), 701.
https://doi.org/10.3390/antiox14060701